Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer.
medical oncology
ovarian carcinoma
practice management
surgical oncology
survey
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Oct 2021
21 Oct 2021
Historique:
received:
17
09
2021
revised:
29
09
2021
accepted:
02
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
The aim of this study was to assess current French practices in the management of patients with advanced epithelial ovarian cancer. a 58-question electronic survey was distributed anonymously to the members of the SFOG (French Society of Gynaecological Oncology), GINECO-ARCAGY (National Investigators Group for Ovarian and Breast Cancer Studies in France) and FRANCOGYN (French research group in oncological and gynaecological surgery). Initial diagnostic workup and staging, pathological data, surgical data, treatments and follow-up strategies were assessed. a total of 107 participants responded to emailed surveys. Most of the respondents were obstetrician-gynaecologists (37.4%), surgical oncologists (34.6%) and medical oncologists (17.8%). According to most (76.8%) participants, less than 50% of patients were eligible for primary debulking surgery (PDS). The LION study criteria were applied in 69.5% of cases during PDS and 39% after chemotherapy. The timing of BRCA testing was very heterogeneous and ranged from 1 to 6 months. The use of bevacizumab as an adjuvant schedule was lower in cases of no residual disease (for 54.5% of respondents) compared to cases of residual disease (for 63.6% of respondents). In cases of BRCA1-2 mutations, olaparib was given by 75.8-84.8% of respondents, whereas niraparib was given in cases of BRCA wild-type diseases. this survey provides an extensive and a unique review of current French practices in the management of patients with advanced epithelial ovarian cancer in 2021.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to assess current French practices in the management of patients with advanced epithelial ovarian cancer.
METHOD
METHODS
a 58-question electronic survey was distributed anonymously to the members of the SFOG (French Society of Gynaecological Oncology), GINECO-ARCAGY (National Investigators Group for Ovarian and Breast Cancer Studies in France) and FRANCOGYN (French research group in oncological and gynaecological surgery). Initial diagnostic workup and staging, pathological data, surgical data, treatments and follow-up strategies were assessed.
RESULTS
RESULTS
a total of 107 participants responded to emailed surveys. Most of the respondents were obstetrician-gynaecologists (37.4%), surgical oncologists (34.6%) and medical oncologists (17.8%). According to most (76.8%) participants, less than 50% of patients were eligible for primary debulking surgery (PDS). The LION study criteria were applied in 69.5% of cases during PDS and 39% after chemotherapy. The timing of BRCA testing was very heterogeneous and ranged from 1 to 6 months. The use of bevacizumab as an adjuvant schedule was lower in cases of no residual disease (for 54.5% of respondents) compared to cases of residual disease (for 63.6% of respondents). In cases of BRCA1-2 mutations, olaparib was given by 75.8-84.8% of respondents, whereas niraparib was given in cases of BRCA wild-type diseases.
CONCLUSION
CONCLUSIONS
this survey provides an extensive and a unique review of current French practices in the management of patients with advanced epithelial ovarian cancer in 2021.
Identifiants
pubmed: 34768353
pii: jcm10214829
doi: 10.3390/jcm10214829
pmc: PMC8585030
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gynecol Oncol. 2009 Jul;114(1):26-31
pubmed: 19395008
Eur J Cancer. 2021 Mar;146:30-47
pubmed: 33578357
Drug Des Devel Ther. 2017 Dec 06;11:3471-3479
pubmed: 29255348
Lancet Oncol. 2018 Dec;19(12):1680-1687
pubmed: 30413383
J Gynecol Obstet Hum Reprod. 2019 Jun;48(6):379-386
pubmed: 30936025
Eur J Surg Oncol. 2021 Feb;47(2):360-366
pubmed: 32863097
Int J Gynecol Cancer. 2015 Jul;25(6):1121-7
pubmed: 25860841
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
N Engl J Med. 2019 Feb 28;380(9):822-832
pubmed: 30811909
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Int J Gynecol Cancer. 2020 Jun;30(6):845-852
pubmed: 32341114
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Gynecol Oncol. 2006 Nov;103(2):559-64
pubmed: 16714056
Ann Oncol. 2021 Oct;32(10):1300-1303
pubmed: 34293462
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Gynecol Oncol. 2010 Oct;119(1):18-21
pubmed: 20673970
Eur J Surg Oncol. 2014 Jul;40(7):891-8
pubmed: 24378007
Cochrane Database Syst Rev. 2019 Oct 31;2019(10):
pubmed: 31684686
Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664
pubmed: 33028623
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Bull Cancer. 2021 Sep;108(9):806-812
pubmed: 34217437
J Gynecol Obstet Hum Reprod. 2019 Jun;48(6):369-378
pubmed: 30936027
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
J Clin Med. 2020 Jul 29;9(8):
pubmed: 32751303
Gynecol Oncol. 2010 Oct;119(1):53-9
pubmed: 20580063
J Natl Cancer Inst. 2005 Apr 20;97(8):560-6
pubmed: 15840878
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Ann Oncol. 2000 Sep;11(9):1131-5
pubmed: 11061607
J Natl Compr Canc Netw. 2021 Feb 02;19(2):191-226
pubmed: 33545690
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Jpn J Clin Oncol. 2016 Aug;46(8):718-26
pubmed: 27272175
Eur J Obstet Gynecol Reprod Biol. 2018 Apr;223:98-102
pubmed: 29525755
Cancers (Basel). 2021 Mar 30;13(7):
pubmed: 33808284
Gynecol Oncol. 2022 Aug;166(2):219-229
pubmed: 35690498
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Cancers (Basel). 2020 Mar 24;12(3):
pubmed: 32213920
J Clin Oncol. 2010 Apr 1;28(10):1733-9
pubmed: 20194855
J Gynecol Obstet Hum Reprod. 2021 Oct;50(8):102133
pubmed: 33789183
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
Gynecol Oncol. 2001 Sep;82(3):489-97
pubmed: 11520145
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Am J Obstet Gynecol. 2010 Sep;203(3):e10-1; author reply e11
pubmed: 20594544